Plasma Levels of Matrix Metalloproteinase-2 (MMP-2) and Tissue Inhibitors of Metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as Noninvasive Markers of Liver Disease in Chronic Hepatitis C Comparison Using ROC Analysis

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Digestive Diseases and Sciences

• Publication date

  1999-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1023/A:1026630129025
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum levels of tissue inhibitor of metalloproteinases-2 and of precursor form of matrix metalloproteinase-2 in patients with liver disease.

  2008cited by this paper
• Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.

  1997cited by this paper
• Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease.

  1997cited by this paper
• Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response.

  1997cited by this paper
• Fibrosis and other histological features in chronic hepatitis C virus infection: a statistical model.

  1996cited by this paper
• Significance of serum tissue inhibitor of metalloproteinases-1 in various liver diseases.

  1996cited by this paper
• Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C.

  1996cited by this paper
• Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver.

  1996cited by this paper
• Histological grading and staging of chronic hepatitis.

  1995cited by this paper
• Epidemiology of Hepatitis C in the East

  1995cited by this paper
• Clinical outcomes after transfusion-associated hepatitis C.

  1995cited by this paper
• Relationship of aminotransferases to liver histological status in chronic hepatitis C.

  1995cited by this paper
• Development of an enzyme-linked immunosorbent assay to measure total TIMP-1 (free TIMP-1 and TIMP-1 in combination with matrix-metalloproteinases) and measurement of TIMP 1 and CRP in serum.

  1995cited by this paper
• Hepatitis C virus and liver diseases

  1994cited by this paper
• A One‐Step Sandwich Enzyme Immunoassay for Human Matrix Metalloproteinase 9 Using Monoclonal Antibodies

  1994cited by this paper
• Degradation of matrix proteins in liver fibrosis.

  1994cited by this paper
• Tissue inhibitor of metalloproteinase is increased in the serum of precirrhotic and cirrhotic alcoholic patients and can serve as a marker of fibrosis

  1994cited by this paper
• Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver.

  1994cited by this paper
• A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies.

  1993cited by this paper
• Clinical evaluation of serum tissue inhibitor of metalloproteinases‐1 levels in patients with liver diseases

  1993cited by this paper
• Serum tissue inhibitor of metalloproteinases in patients with chronic liver disease and with hepatocellular carcinoma.

  1993cited by this paper
• A computer program for non-parametric receiver operating characteristic analysis.

  1993cited by this paper
• Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues.

  1990cited by this paper
• Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug users.

  1990cited by this paper
• Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases. An application for rheumatoid arthritis serum and plasma.

  1990cited by this paper
• Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

  1989cited by this paper
• The use of relative operating characteristic (ROC) curves in test performance evaluation.

  1986cited by this paper
• A study of liver biopsies and liver disease among hemophiliacs.

  1985cited by this paper
• Statistical methods for rates and proportions

  1973cited by this paper
• Epidemiology of hepatitis.

  1965cited by this paper

• Associations among serum levels of MMP-1, MMP-2, and METAVIR fibrosis score in patients with nonalcoholic fatty liver disease

  2025cites this paper
• A polysaccharide from Codonopsis pilosula roots attenuates carbon tetrachloride-induced liver fibrosis via modulation of TLR4/NF-κB and TGF-β1/Smad3 signaling pathway.

  2023cites this paper
• Enzymes of Fibrosis in Chronic Liver Disease

  2022cites this paper
• Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers

  2022cites this paper
• Innovated pirfenidone loaded lecithin nanocapsules for targeting liver fibrosis: Formulation, characterization and in vivo study.

  2022cites this paper
• Breath-Taking Perspectives and Preliminary Data toward Early Detection of Chronic Liver Diseases

  2021cites this paper
• Potential role of noninvasive biomarkers during liver fibrosis

  2021cites this paper
• Noninvasive Biomarkers for Liver Fibrosis

  2020cites this paper
• Prostate cancer survivors with symptoms of radiation cystitis have elevated fibrotic and vascular proteins in urine

  2020cites this paper
• Tissue inhibitor of metalloproteinase 1 and AST‐to‐Platelet Ratio Index as noninvasive biomarkers predict allograft fibrosis after pediatric liver transplantation

  2019cites this paper
• HBOA ameliorates CCl4-incuded liver fibrosis through inhibiting TGF-β1/Smads, NF-κB and ERK signaling pathways.

  2019cites this paper
• Matrix metalloproteinase-2: Not (just) a "hero" of the past.

  2019cites this paper
• Enhanced liver fibrosis test in a group of patients with alcohol abuse

  2019cites this paper
• Diagnostic Methods for Cirrhosis and Portal Hypertension

  2018cites this paper
• MMP-2 gene expression at mRNA level in HBV and HCV infected patients.

  2018cites this paper
• Diagnosis and staging of fibrosis in patients with chronic hepatitis C: comparison and critical overview of current strategies

  2018cites this paper
• Stratified medicine : an exploration of the utility of non-invasive serum markers for the management of chronic liver diseases

  2018cites this paper
• Extracellular Matrix Remodeling with Focus on Biochemical Markers in Liver Fibrosis: Limitations and Possibilities

  2018cites this paper
• The role of the enzyme systems of the organism in the development of chronic liver diseases

  2018cites this paper
• Dysregulation of fibrosis related genes in HCV induced liver disease.

  2018cites this paper
• Non-invasive Serum Markers of Fibrosis

  2018cites this paper
• Traditional Markers in Liver Disease

  2017cites this paper
• Surrogate Markers of Liver Fibrosis in Primary Sclerosing Cholangitis ( PSC )

  2017cites this paper
• Assessment of Schistosomiasis Induced Morbidity in the Philippines

  2017cites this paper
• Liver and serum expression of matrix metalloproteinases in asymptomatic pediatric liver transplant recipients

  2017cites this paper
• TNF-alpha 308 SNP Rs3091256 GG Genotype is Strongly Associated with Fibrosis in Patients with Chronic Hepatitis C

  2017cites this paper
• Circulating Survivin and TIMP-1 in Hepatitis C Virus Associated Liver Fibrosis

  2017cites this paper
• Panel of three novel serum markers predicts liver stiffness and fibrosis stages in patients with chronic liver disease

  2017cites this paper
• Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage.

  2016cites this paper
• Noninvasive Markers to Assess Liver Fibrosis

  2016cites this paper
• Role of Noninvasive Fibrosis Methods in Management of Chronic Hepatitis B Virus

  2016cites this paper
• Tissue Inhibitor of Metalloproteinases 1 and 2 (TIMP-1 and TIMP-2)

  2016cites this paper
• New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article

  2016cites this paper
• Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy?

  2016cites this paper
• Biomarkers of Extracellular Matrix Remodeling in Liver Diseases

  2015cites this paper
• Plasma levels of matrix metalloproteinase-2 and -9 in male and female patients with cirrhosis of different aetiologies

  2015cites this paper
• Non-invasive diagnosis of liver fibrosis and cirrhosis.

  2015cites this paper
• Tissue Inhibitors of Metalloproteinase-1 and 2 and Obesity Related Non-Alcoholic Fatty Liver Disease: Is There a Relationship?

  2015cites this paper
• To Biopsy or not to Biopsy: A Review of Guidelines on the use of Methotrexate

  2015cites this paper
• Cellular mechanisms of myofibroblast differentiation and dysfunctions in wound healing

  2014cites this paper
• Non-invasive Assessment of Liver Fibrosis Using Serum Markers

  2014cites this paper
• Correlation of PlasmaMMP-1 and TIMP-1 Levels and the Colonic Mucosa Expressions in Patients with Ulcerative Colitis

  2014cites this paper
• Non invasive tools for the diagnosis of liver cirrhosis.

  2014cites this paper
• The chronic enteropathogenic disease schistosomiasis.

  2014cites this paper
• Anti-glomerular Basement Membrane Antibodies and Cystatin C as a Predictive Markers of Renal Dysfunction in Chronic Hepatitis C Virus Patients

  2014cites this paper
• Helenalin attenuates alcohol-induced hepatic fibrosis by enhancing ethanol metabolism, inhibiting oxidative stress and suppressing HSC activation.

  2014cites this paper
• Chronic hepatitis C and liver fibrosis.

  2014cites this paper
• Scores d’évaluation biologique de la fibrose hépatique

  2014cites this paper
• Markers in nonalcoholic steatohepatitis.

  2013cites this paper
• From fatty liver to fibrosis: a tale of "second hit".

  2013cites this paper
• Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection

  2013cites this paper
• Performance of diagnostic biomarkers in predicting liver fibrosis among hepatitis C virus-infected Egyptian children.

  2013cites this paper
• Effect of Age, Tumor Risk, and Comorbidity in a U.S. Population–Based Cohort of Men With Prostate Cancer

  2013cites this paper
• Association between matrix metalloproteinase (MMP)‐2, MMP‐9 and total antioxidant status of patients with asymptomatic hepatitis C virus infection

  2013cites this paper
• Significance of apoptotic markers Bcl-2 , CD4+ T cells , hepatocyte growth factor and metalloproteinase -9 in infected patients with HCV

  2013cites this paper
• Molecular Serum Markers of Liver Fibrosis

  2012cites this paper
• Genomics and proteomics in liver fibrosis and cirrhosis

  2012cites this paper
• Serum N-glycomic markers in combination with panels improves the diagnosis of chronic hepatitis B.

  2012cites this paper
• Non-invasive assessment of liver fibrosis

  2012cites this paper
• Technical aspects of genomics and proteomics in chronic liver disease

  2012cites this paper
• Clinical Utility of Serum Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinase-2 Concentrations in the Assessment of Liver Fibrosis due to Chronic Hepatitis B

  2012cites this paper
• Associations among serum concentrations of interleukin-18, matrix metalloproteinase-2 (MMP-2), tissue inhibitor of metalloproteinase-1 (TIMP-1) and METAVIR fibrosis score in patients with chronic hepatitis

  2012cites this paper
• NON INVASIVE LABORATORY MARKER FOR THE DIAGNOSIS AND ASSESSMENT OF SEVERITY OF LIVER FIBROSIS IN CHRONIC HEPATITIS C PATIENTS

  2012cites this paper
• Modulation of plasma matrix metalloproteinase 9 and its inhibitors by vitamin D.

  2012cites this paper
• Composting of wine industry wastes and their use as a substrate for growing soilless ornamental plants

  2012cites this paper
• Screening for hepatitis C virus infection.

  2012cites this paper
• Automated quantification of serum hyaluronic acid for non-invasive assessment of liver fibrosis in chronic hepatic diseases

  2011cites this paper
• COMPLICATIONS OF ALCOHOLIC LIVER DISEASE AND DIAGNOSTIC MARKERS

  2011cites this paper
• KOMPLIKACIJE ALKOHOLNE BOLESTI JETRE I DIJAGNOSTIČKI MARKERI

  2011cites this paper
• Evaluation of Fibrosis Progression by Noninvasive Biochemical Markers in Egyptian Patients with Chronic Hepatitis B

  2011cites this paper
• Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus‐coinfected patients

  2011cites this paper
• Non-Invasive Biomarkers for Hepatic Fibrosis

  2011cites this paper
• Diagnostic value of multiple biomarker panel for prediction of significant fibrosis in chronic hepatitis C.

  2011cites this paper
• Hydroxysafflor yellow A protects against chronic carbon tetrachloride-induced liver fibrosis.

  2011cites this paper
• Non-Invasive markers for hepatic fibrosis

  2011cites this paper
• Usefulness of Multiple Biomarkers for the Prediction of Significant Fibrosis in Chronic Hepatitis B

  2011cites this paper
• Non-invasive assessment of liver fibrosis: it is time for laboratory medicine

  2011cites this paper
• Clinical Benefits of Biochemical Markers of Fibrosis in Egyptian Children With Chronic Liver Diseases

  2010cites this paper
• Inhibitory Effect of Antisense Oligonucleotide Targeting TIMP-2 on Immune-Induced Liver Fibrosis

  2010cites this paper
• Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients.

  2010cites this paper
• Differential Elevation of Serum Matrix Metalloproteinases 1 and 2 in Pediatrics Chronic Liver Diseases

  2010cites this paper
• aggregation MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet Platelet release of trimolecular complex components

  2010cites this paper
• Increased urinary lipocalin-2 reflects matrix metalloproteinase-9 activity in chronic hepatitis C with hepatic fibrosis.

  2010cites this paper
• Circulating markers of liver fibrosis progression.

  2010cites this paper
• Paediatric cholestatic liver disease: Diagnosis, assessment of disease progression and mechanisms of fibrogenesis.

  2010cites this paper
• [Liver fibrosis in hepatitis B: a dynamic process].

  2010cites this paper
• Hepatoprotective role of bis-demethoxy curcumin analog on the expression of matrix metalloproteinase induced by alcohol and polyunsaturated fatty acid in rats

  2010cites this paper
• Correlation of Plasma MMP-1 and TIMP-1 Levels and the Colonic Mucosa Expressions in Patients with Ulcerative Colitis

  2009cites this paper
• Systematic review: non‐invasive methods of fibrosis analysis in chronic hepatitis C

  2009cites this paper
• NON INVASIVE EVALUATION OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS B AND C

  2009cites this paper
• Noninvasive assessment of liver fibrosis. Serum markers and transient elastography (FibroScan).

  2009cites this paper
• A local imbalance between MMP and TIMP may have an implication on the severity and course of appendicitis

  2008cites this paper
• Diagnosis and quantitation of fibrosis.

  2008cites this paper
• VİRAL HEPATİTLERDE MATRİKS METALLOPROTEİNAZLARIN VE İNHİBİTÖRLERİNİN EKSPRESYON PATERNLERİ VE BUNLARIN FİBROZİS İLE İLİŞKİLERİ

  2008cites this paper
• Matrix metalloproteinases and their tissue inhibitors in children with chronic hepatitis B treated with lamivudine.

  2007cites this paper
• Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C.

  2007cites this paper
• Noninvasive biochemical markers of liver fibrosis.

  2006cites this paper
• Do we still need a liver biopsy? Are the serum fibrosis tests ready for prime time?

  2006cites this paper
• Progression of fibrosis in hepatitis C with and without schistosomiasis: Correlation with serum markers of fibrosis

  2006cites this paper
• Efficacy of Serum Hyaluronic Acid Level for Predicting Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease

  2006cites this paper